Overview

A Randomized, Double-Blind Phase II Study of Adjuvant Pembrolizumab Versus Placebo in Head and Neck Cancers at High Risk for Recurrence- the PATHWay Study

Status:
Recruiting

Trial end date:
2023-06-01

Target enrollment:

Participant gender:

Summary

A placebo-controlled, randomized study using adjuvant pembrolizumab treatment for one year in order to potentially improve progression free survival in a squamous cell carcinoma of the head and neck cohort at high-risk for recurrence.

Phase:

Phase 2

Details

Lead Sponsor:

University of Chicago

Treatments:

Pembrolizumab